Where the category stands in May 2026 — what's available, who to trust, what costs what. 22-min read, medically reviewed.
Read the guideAn independent overview of the compounded-GLP-1 telehealth market and the providers we cover — market size, what the FDA changed, and an honest read on each.
View the provider overviewOverview & reviewsPrimers for newcomers and deep dives for the curious. The foundation articles are published; more are in the pipeline.
View all Learn articlesWhat compounded and branded semaglutide and tirzepatide actually cost, from each provider's own published pricing.
Two recovery peptides compared — mechanism, what the human evidence does (and does not) show, safety, and whether stacking is worth it.
BPC-157 and TB-500 are the two peptides that dominate injury-recovery forums, usually discussed together and often stacked. Mechanistically they're doing different things — BPC-157 drives angiogenesis through nitric oxide [2], TB-500 regulates the actin cytoskeleton to speed cell migration [10]. Neither is FDA-approved for any indication. The human evidence is thin for BPC-157 and, for the TB-500 fragment specifically, essentially nonexistent — most clinical data belongs to its parent protein, thymosin beta-4 [13].
The honest answer goes like this: one of these peptides has a small but real toe-hold in human research, the other has almost none, both are sold in a gray market that pretends regulatory categories don't exist, and the most popular use case — stacking them — rests entirely on mechanistic theorizing and self-reported anecdote. Here's what's known, what's guessed, and what's marketing.
The recovery-peptide space is crowded, but BPC-157 and TB-500 occupy a unique slot. They're both small, both injectable, both pitched as systemic repair agents rather than performance enhancers, and both circulate without FDA approval for any therapeutic use. That last detail makes them culturally adjacent to anabolic steroids in some communities — gray-market substances with passionate user bases and a thin veneer of "research only" disclaimers — but the pitch is different. The pitch is healing, not muscle. Tendons that won't recover. Achilles strains that linger. Gut symptoms no gastroenterologist has fixed.
What unites them in user lore is the claim that they accelerate the body's own repair machinery. What divides them, in theory, is where that repair happens. BPC-157 has a reputation for local tissue work — gut lining, tendons, ligaments. TB-500 is sold as the systemic counterpart, traveling through tissue and recruiting cells to sites of injury. Whether either reputation is earned by the data is a separate question.
BPC-157 is a synthetic pentadecapeptide — fifteen amino acids — based on a partial sequence found in human gastric juice. "BPC" stands for Body Protection Compound. The parent protein is a protective factor secreted by the stomach, and BPC-157 is the engineered subunit that researchers in Croatia (largely the group around Predrag Sikirić) have studied since the early 1990s. It's stable against gastric acid, unusual for a peptide and the reason oral dosing is even theoretically viable [2].
TB-500 is a synthetic fragment of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid protein found in essentially every mammalian cell. The fragment sold as TB-500 (Ac-LKKTETQ, residues 17–23) reproduces the actin-binding motif of the parent protein [10]. Tβ4 itself is one of the most abundant intracellular proteins in the body — present in platelets, white blood cells, and wound fluid — and has been studied in cardiovascular regeneration, corneal repair, and dermal wound healing [12].
Same general category, very different molecular biographies. BPC-157 is engineered protection. TB-500 is a fragment of something you already make.
The mechanistic stories diverge almost immediately.
BPC-157's central pathway is angiogenesis through nitric oxide. It enhances VEGFR2 expression and activates the PI3K/Akt/eNOS cascade, producing new blood vessels and better delivery of oxygen and nutrients to damaged tissue. It also runs a parallel route — Src kinase, caveolin-1, eNOS — that works when the VEGF arm is blocked [3]. Beyond vasculature, it upregulates heme oxygenase-1, supports fibroblast activity and collagen synthesis, and modulates glutamatergic and other signaling in ways that complicate the "just a healing peptide" framing [2]. Half-life is short — under thirty minutes in animal models, with plasma levels returning to baseline within a day [2].
TB-500's central pathway is actin sequestration. Thymosin beta-4 binds G-actin monomers and regulates their availability for polymerization into the filaments cells use to migrate, divide, and rebuild structure [10]. In wound contexts that translates to faster recruitment of stem cells and endothelial progenitor cells to the injury site, plus modulation of inflammatory cytokines via NF-κB suppression [12]. There's also evidence in rodent cardiac and corneal models that Tβ4 reduces fibrosis and accelerates re-epithelialization [11][12]. The pharmacokinetics of the synthetic TB-500 fragment in humans are not characterized — most of what's cited is extrapolated from animal Tβ4 work.
Both pathways converge on tissue repair. They get there by different cellular routes — vessels and NO for one, cytoskeletal dynamics and cell migration for the other.
In the published preclinical literature, BPC-157's strongest signals are in gastrointestinal protection (rat gastric-ulcer models, where it accelerates ulcer closure and protects the mucosal lining) and musculoskeletal repair (tendon and ligament transection models showing improved collagen organization and faster mechanical recovery). There's also rodent work on neurological models. None of this has been replicated in human trials of comparable rigor [1].
TB-500's strongest preclinical signals — really, its parent protein's — are in cardiovascular and dermal tissue. Tβ4 has been studied in mouse models of myocardial infarction with reported reductions in scar tissue, and corneal wound-healing work (including RegeneRx's RGN-259 program) is the most clinically developed application of the parent peptide [12][13]. Tendon and skeletal-muscle data exist in animals but are thinner than BPC-157's portfolio in that area.
The user-community framing — BPC-157 for local tissue, TB-500 for systemic recruitment — has a defensible mechanistic basis but oversimplifies the data. Both peptides act locally and systemically depending on route and dose. The cleaner statement: BPC-157 has more preclinical depth in gut and tendon work; TB-500's parent protein has more depth in cardiac and corneal work; neither has a human evidence base in injury recovery worth calling clinical.
This is where the picture gets uncomfortable for anyone selling certainty.
The published human evidence for BPC-157 is three small uncontrolled pilot studies and case series, all in the same journal — Alternative Therapies in Health and Medicine — and all authored by the same primary investigator, a clinician with commercial exposure to the outcomes [4][5][6]. A knee-pain series reports symptom improvement after intra-articular injection in a handful of patients, no control group, no blinding [4]. An interstitial-cystitis pilot enrolled twelve women, gave them 10 mg BPC-157 injected into the bladder wall, and reported all twelve improved [5]. An IV safety pilot reported no adverse events at doses up to 20 mg [6].
A Phase I pharmacokinetics trial (NCT02637284) was registered in December 2015 by PharmaCotherapia, tested oral tablets up to 6 mg per dose in 42 healthy volunteers, and found the compound well tolerated with no clinically meaningful changes in safety biomarkers; results were never published in a major journal [7].
A Phase II randomized, double-blind, placebo-controlled trial for acute grade II hamstring strain (NCT07437547) was registered in February 2026 by Hudson Biotech and is recruiting, with 120 participants planned and co-primary endpoints of return-to-sport time and MRI-assessed injury volume [8]. That's the first methodologically serious test of BPC-157 for an injury indication in humans, and it has no results yet.
Small samples, real signal in animals, almost no signal in humans. A 2025 narrative review put it bluntly: until well-designed human trials are conducted and published, BPC-157 shouldn't be recommended for clinical use in musculoskeletal medicine [1]. The "500,000 prescriptions" figure that circulates in marketing — derived from a survey of 503A compounding pharmacies — is anecdotal pharmacy data, not safety evidence.
TB-500's situation is similar in shape and worse in detail.
The parent protein, thymosin beta-4, has been studied in human trials — primarily by RegeneRx — for dry eye, pressure ulcers, and venous stasis ulcers. A Phase I trial of intravenous recombinant Tβ4 (54 healthy volunteers, 0.05–25 μg/kg) was well tolerated, and small Phase II trials reported encouraging signals for chronic-wound and corneal healing [13]. None of that work has produced an FDA-approved product, and none directly addresses tendon, ligament, or muscle injury.
The synthetic fragment sold as TB-500 has not been the subject of dedicated, published human clinical trials for injury repair [10]. The mechanistic story is reasonable, the parent-protein data is suggestive, and the leap to "TB-500 accelerates tendon recovery in humans" is exactly that — a leap from in-vitro and animal data plus user reports.
For what it's worth, the World Anti-Doping Agency lists thymosin beta-4 and its derivatives, explicitly including TB-500, on its Prohibited List under section S2 — a decision made on the assumption it might confer a recovery benefit, not on conclusive efficacy data [14].
In the small pilot studies that exist for BPC-157, no serious adverse events have been reported in short-term use [4][5][6]. The FDA's FAERS database does contain voluntary reports for BPC-157 — including kidney-related signals — but the counts are unreliable (the same top-line figures recur across unrelated drug queries), FAERS doesn't establish causation, and it reflects off-label use in an unregulated market [15]. The theoretical concerns are real: BPC-157 upregulates VEGFR2 and eNOS, both implicated in tumor angiogenesis. The preclinical data is genuinely mixed — some studies show BPC-157 inhibits uncontrolled proliferation, others raise the pathologic-angiogenesis concern — and long-term human safety data simply doesn't exist [1].
TB-500's safety profile in humans is even less characterized. Full-length Tβ4 was well tolerated in the trials conducted, with mostly mild injection-site reactions and transient headache [13], but the synthetic TB-500 fragment has not been independently safety-tested in any program that's produced published results. The theoretical oncological concern is similar in shape — anything that promotes angiogenesis and cell migration carries hypothetical risk in the presence of malignancy.
The bigger near-term safety problem for both peptides has nothing to do with their pharmacology. Gray-market products carry independent risks: contamination, endotoxins, incorrect peptide identity, inaccurate dosing, sterility failures. That risk applies to anything bought outside a regulated supply chain — and right now, almost everything in this category is.
The stacking rationale, when it's articulated at all, goes like this: BPC-157 promotes local angiogenesis and supports collagen and fibroblast activity; TB-500 promotes cell migration and recruits progenitor cells to the injury site. Different mechanisms, theoretically complementary, no obvious pharmacological conflict. It's not unreasonable as a hypothesis.
What it isn't is evidence. There are no published human trials of the combination, and no animal studies that meaningfully test whether two peptides outperform either alone. The entire stacking case rests on mechanistic theorizing plus user reports — and user reports in a gray market, where placebo, regression to the mean, and reporting bias all run unchecked, are not evidence of additive efficacy.
The honest framing: stacking BPC-157 and TB-500 might be additive, might be redundant, might introduce unknown interactions. Nobody has tested it in a way that would tell us which — while the cost, the contamination exposure, and the unknown long-term risk all roughly double.
In late 2023, the FDA placed BPC-157 and a group of other peptides in Category 2 of bulk drug substances under Section 503A — effectively prohibiting compounding pharmacies from preparing them, on the basis of stated safety risks [9]. That shifted the landscape sharply: research-only sales continued through gray-market channels, but legitimate compounding stopped.
On April 15, 2026 the FDA removed both peptides from Category 2, along with ten others, and referred the question to its advisory committee [9]. Removal is not approval: it lifted a stated prohibition without granting a pathway.
That committee met on July 23, 2026 and voted to recommend both for the 503A positive list — BPC-157 and TB-500 each 8 in favour, 6 against, 1 abstention, with free base and acetate voted separately and landing the same way, and in both cases against the agency reviewers' own proposal to reject them [16]. The recommendation is non-binding, FDA has issued no final determination, and adding a substance to the list requires rulemaking that has not begun. See our report on the vote.
So neither peptide is on the list today. Legal compounding under 503A requires meeting one of three criteria — a USP monograph, being a component of an approved drug, or placement on the 503A positive list — and as of now both meet none of them.
TB-500's regulatory status is structurally similar: never FDA-approved, not currently eligible for 503A/503B compounding, and circulating almost entirely through "research use only" channels [10]. Online sale of either peptide labeled "for research only" but intended for human therapeutic use constitutes misbranding and distribution of an unapproved new drug under current FDA interpretation — regardless of what the product page says.
On sport: TB-500 is explicitly prohibited at all times under WADA section S2 [14]. BPC-157 is not named on the WADA list, but as an unapproved pharmacological substance it most likely falls under S0 (non-approved substances); any competitive athlete tested under WADA, USADA, or NCAA protocols should treat both as prohibited.
| BPC-157 | TB-500 | |
|---|---|---|
| Molecular identity | Synthetic 15-aa pentadecapeptide derived from a gastric protective protein | Synthetic fragment (Ac-LKKTETQ, residues 17–23) of thymosin beta-4, a 43-aa natural protein |
| Primary mechanism | VEGFR2- and Src/caveolin-1-mediated angiogenesis; nitric oxide; collagen support | Actin sequestration; cell migration; progenitor recruitment; anti-fibrotic effects |
| Preclinical strength | Gut, tendon/ligament, neurological models | Cardiac, corneal, dermal wound healing (mostly the parent protein) |
| Human trial evidence | 3 small uncontrolled pilots (same author, low-tier journal); Phase I PK done, unpublished; Phase II hamstring trial recruiting | No dedicated published human trials of the fragment; parent protein has small trials in other indications |
| Short-term safety | No serious AEs in pilots; FAERS reports exist but are unreliable | Limited human data; parent protein tolerated in small trials |
| Long-term safety | Unknown; oncological theoretical concerns unresolved | Unknown; similar theoretical concerns |
| Stacking evidence | Mechanistic rationale only; no controlled data on the combination | Same |
| FDA status | Unapproved; 503A Category-2 status in flux in 2026; not approved | Unapproved; not compounding-eligible |
| Anti-doping status | Not named by WADA; likely prohibited under S0 | Explicitly WADA-prohibited (S2) |
The supported claims, narrowly: BPC-157 has a real preclinical signal for tissue repair in gut, tendon, and ligament models, plus a small handful of human pilot studies suggesting short-term tolerability. TB-500's parent protein has clinical-trial activity in dermal and corneal repair. Both have mechanistically plausible stories for why they might accelerate injury recovery.
The speculative claims, all of them: that either peptide reliably accelerates injury recovery in humans at the doses people self-administer; that the combination outperforms either alone; that gray-market products deliver what the label claims; that short-term tolerability in twelve people predicts long-term safety in tens of thousands; that mechanistic plausibility substitutes for controlled human data.
The Phase II hamstring trial now recruiting for BPC-157 is the first study designed to answer the question most users are actually asking [8]. Its results, when they arrive, will tell us more than the entire current human literature combined. Until then, the honest read: these are interesting peptides with thin human evidence and unresolved long-term safety questions, available mostly through channels that introduce contamination and identity risks independent of the molecules themselves. The certainty in the user community far exceeds the certainty in the data — and that gap is the most important thing to understand about either one.
Neither has human evidence strong enough to call clinical. BPC-157 has more preclinical depth in gut and tendon models plus a few small human pilots; TB-500's evidence belongs mostly to its parent protein in cardiac and corneal indications [1][13]. For a discrete local injury the preclinical case favors BPC-157; for distributed tissue damage, TB-500's biology is the better story — but both remain unproven in humans.
People do, on a plausible mechanistic rationale, but there's no controlled human or animal evidence that the combination outperforms either alone — and stacking roughly doubles cost, contamination exposure, and unknown long-term risk.
TB-500 is explicitly banned by WADA (S2) [14]. BPC-157 isn't named but most likely falls under S0 (non-approved substances). Tested athletes should treat both as prohibited.
Editorial note: Informational only — not medical advice. BPC-157 and TB-500 are not FDA-approved for any therapeutic indication. Decisions about peptide use should be made with a licensed healthcare provider familiar with your medical history and the regulatory status of these substances. See our methodology. § 14 / References 1. "Regeneration or Risk?" — narrative review of BPC-157 evidence. PMC, 2025. (Tier B — narrative review) https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177 2. Pharmacokinetics and mechanism of BPC-157. Front Pharmacol 2022. (Tier A — peer-reviewed) https://pmc.ncbi.nlm.nih.gov/articles/PMC9794587 3. BPC-157 and the Src–caveolin-1–eNOS angiogenic pathway. Sci Rep 2020. (Tier A — peer-reviewed) https://www.nature.com/articles/s41598-020-74022-y 4. Lee E, Padgett B. Intra-articular BPC-157 for knee pain — case series. Altern Ther Health Med 2021;27(4):8–13. (Tier C — small uncontrolled case series) 5. Lee E, Walker C, Ayadi B. Intravesical BPC-157 for interstitial cystitis — pilot. Altern Ther Health Med 2024;30(10):12–17. (Tier C — uncontrolled pilot) 6. Lee E, Burgess K. Intravenous BPC-157 safety pilot. Altern Ther Health Med 2025;31:20–24. (Tier C — uncontrolled pilot) 7. Phase I pharmacokinetics of oral BPC-157 (PCO-02) in healthy volunteers — NCT02637284. (Tier A — trial registry) https://clinicaltrials.gov/study/NCT02637284 8. Phase II RCT of BPC-157 for acute grade II hamstring strain — NCT07437547 (Hudson Biotech; recruiting). (Tier A — trial registry) https://clinicaltrials.gov/study/NCT07437547 9. FDA — Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (503A Category 2; incl. BPC-157, TB-500). (Tier A — FDA) https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks 10. Philp D, Kleinman HK, et al. The actin-binding domain of thymosin beta-4 (TB-500 sequence) is necessary and sufficient for angiogenic activity. PMID 14500546. (Tier A — peer-reviewed) https://pubmed.ncbi.nlm.nih.gov/14500546/ 11. Goldstein AL, et al. Thymosin beta-4 promotes dermal wound re-epithelialization. PMID 10469335. (Tier A — peer-reviewed) https://pubmed.ncbi.nlm.nih.gov/10469335/ 12. Philp D, Kleinman HK. Thymosin beta-4 in tissue repair — review (dermal, corneal, cardiac). PMID 20536453. (Tier B — review) https://pubmed.ncbi.nlm.nih.gov/20536453/ 13. Treadwell T, Goldstein AL, et al. Thymosin beta-4 accelerates dermal healing — review incl. chronic-wound (stasis/pressure) Phase II data. PMID 23050815. (Tier B — review) https://pubmed.ncbi.nlm.nih.gov/23050815/ 14. World Anti-Doping Agency — Prohibited List, Section S2 (thymosin beta-4 and derivatives, incl. TB-500). (Tier A — WADA) https://www.wada-ama.org/en/prohibited-list 15. FDA Adverse Event Reporting System (FAERS). (Tier C — passive surveillance; counts unreliable) https://open.fda.gov/drug/event/ 16. FDA Pharmacy Compounding Advisory Committee, meeting of July 23–24, 2026 — agenda, and the official webcast into which the vote results were read (BPC-157 8–6–1 at 4:43:03 and 4:52:43; TB-500 8–6–1 at 9:48:35 and 9:54:09). (Tier A — FDA) https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 and https://youtube.com/live/DhDC0DAYdBI --- Editorial note: Informational only — not medical advice. Neither BPC-157 nor TB-500 is an FDA-approved drug, neither is on the 503A positive list, and the regulatory position described here is unsettled — see our report on the July 2026 advisory vote for the current state. Decisions about peptide therapy should be made with a licensed healthcare provider familiar with your medical history. See our methodology. Last reviewed July 2026.